Capoxigem
     ·Capoxigem: Bibliography
     ·Capoxigem: Scientific Presentations
     ·Capoxigem: Clinical Trials
     ·COX-2 in Cancer: Bibliography
TG02
TG03
ProGEM™

AACR 2011 Annual Meeting, April 2011: Inhibition of COX-2 with apricoxib enhances the efficacy of standard therapy in preclinical models of human pancreatic cancer

ASCO 2011 Gastrointestinal Cancers Symposium, January 2011: Preclinical Antitumor Activity and Mechanisms of Action of Apricoxib, a Clinical Cox-2 Inhibitor

ASCO Annual Meeting June 2010: APRiCOT-P: A Phase II Randomized Placebo Controlled Study of Apricoxib, a Potent COX-2 Inhibitor in Combination with Erlotinib and Gemcitabine in Pancreatic Cancer Patients

2008 Chicago Multidisciplinary Symposium in Thorasic Oncology, November 2008: Apricoxib, A New Potent COX-2 Inhibitor in Combination with Erlotinib in Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Patients: A Phase I Study

AACR Annual Meeting, April 2008: Activity of TG01, a Selective COX-2 Inhibitor, Alone and in Combination with Standard Agents in Human Breast Carcinoma Xenografts (Abstract # 5662)

AACR Annual Meeting, April 2008: Activity of TG01, A Selective COX-2 Inhibitor, Alone and in Combination with Docetaxel in Human Non-small Cell Lung Carcinoma Xenografts (Abstract #5663)